316 related articles for article (PubMed ID: 33481276)
1. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
Speck RM; Yu R; Ford JH; Ayer DW; Bhandari R; Wyrwich KW
Headache; 2021 Mar; 61(3):511-526. PubMed ID: 33481276
[TBL] [Abstract][Full Text] [Related]
2. Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine.
Speck RM; Shalhoub H; Wyrwich KW; Yu R; Ayer DW; Ford J; Bush EN; Lipton RB
Headache; 2019 May; 59(5):756-774. PubMed ID: 30861580
[TBL] [Abstract][Full Text] [Related]
3. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.
Ford JH; Ye W; Ayer DW; Mi X; Bhandari S; Buse DC; Lipton RB
J Patient Rep Outcomes; 2023 Apr; 7(1):34. PubMed ID: 37016181
[TBL] [Abstract][Full Text] [Related]
4. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
[TBL] [Abstract][Full Text] [Related]
6. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine.
Seo JG; Park SP
J Oral Facial Pain Headache; 2017 Summer; 31(3):251-256. PubMed ID: 28738110
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).
Kawata AK; Hareendran A; Shaffer S; Mannix S; Thach A; Desai P; Mikol DD; Ortmeier B; Bayliss M; Buse DC
Headache; 2019 Sep; 59(8):1253-1269. PubMed ID: 31168803
[TBL] [Abstract][Full Text] [Related]
9. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
[TBL] [Abstract][Full Text] [Related]
10. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
Houts CR; Wirth RJ; McGinley JS; Cady R; Lipton RB
Headache; 2020 Oct; 60(9):2003-2013. PubMed ID: 32862469
[TBL] [Abstract][Full Text] [Related]
11. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.
Rendas-Baum R; Bloudek LM; Maglinte GA; Varon SF
Qual Life Res; 2013 Jun; 22(5):1123-33. PubMed ID: 22797868
[TBL] [Abstract][Full Text] [Related]
12. Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.
Kawata AK; Hsieh R; Bender R; Shaffer S; Revicki DA; Bayliss M; Buse DC; Desai P; Sapra S; Ortmeier B; Hareendran A
Headache; 2017 Oct; 57(9):1385-1398. PubMed ID: 28857154
[TBL] [Abstract][Full Text] [Related]
13. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
14. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
15. The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines.
Zandifar A; Masjedi SS; Haghdoost F; Asgari F; Manouchehri N; Banihashemi M; Najafi MR; Ghorbani A; Zolfaghari B; Gholamrezaei A; Shaygannejad V; Saadatnia M
ScientificWorldJournal; 2013; 2013():950245. PubMed ID: 24068887
[TBL] [Abstract][Full Text] [Related]
16. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
17. Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome.
Speck RM; Shalhoub H; Ayer DW; Ford JH; Wyrwich KW; Bush EN
J Patient Rep Outcomes; 2019 Jul; 3(1):39. PubMed ID: 31297622
[TBL] [Abstract][Full Text] [Related]
18. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
19. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
[TBL] [Abstract][Full Text] [Related]
20. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1).
Martin BC; Pathak DS; Sharfman MI; Adelman JU; Taylor F; Kwong WJ; Jhingran P
Headache; 2000 Mar; 40(3):204-15. PubMed ID: 10759923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
